These findings highlight the complex interplay between TP53 family isoforms in modulating immune responses via the IFN-γ pathway, suggesting potential therapeutic strategies for targeting these mechanisms in breast cancer treatment [11,112]. This evidence concerns the gene TP53 and breast carcinoma.